Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SMARCA2 | P51531 | 9/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 8/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17233219 | 0.83 | SMARCA2 (0.45) | RECQLSMARCA2SMARCA4LOXLOXL3 | |
| SCHEMBL19062199 | 0.81 | SMARCA2 (0.45) | RECQLSMARCA2SMARCA4LOXLOXL3 | |
| SCHEMBL19030966 | 0.81 | LOX (0.48) | RECQLSMARCA2SMARCA4CYP2D6LOX | |
| SCHEMBL29140596 | 0.79 | GRIN2D (0.46) | RECQLGRIN2DGRIN3BCHRM1ADRA1D | |
| SCHEMBL21608361 | 0.79 | SMARCA2 (0.47) | RECQLSMARCA2SMARCA4LOXLOXL3 | |
| SCHEMBL24615889 | 0.77 | ALDH1A1 (0.48) | SMARCA2SMARCA4CYP2C19 | |
| SCHEMBL11454686 | 0.77 | HRH3 (0.46) | SMARCA2SMARCA4CYP2C19IDH2 | |
| SCHEMBL4635970 | 0.77 | SMARCA2 (0.47) | RECQLSMARCA2SMARCA4LOXLOXL3 | |
| SCHEMBL12764425 | 0.73 | ESR1 (0.44) | RECQLSMARCA2SMARCA4LOXLOXL3 | |
| SCHEMBL7973139 | 0.73 | SMARCA2 (0.37) | RECQLSMARCA2SMARCA4LOXLOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021060281-A1 | PROSTAGLANDIN E2 RECEPTOR EP2/EP4 DUAL ANTAGONIST | ＡＧＣ株式会社 | 2021-04-01 | — | — | WO | disclosed |
| EP-3138840-B1 | THIADIAZOLIDINE DERIVATIVE AS ANTI-ENTEROVIRUS 71 | JIANGSU KANION PHARMACEUTICAL CO LTD (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3138840-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion Pharmaceutical Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| WO-2015165340-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | 南京明德新药研发股份有限公司 | 2015-11-05 | — | — | WO | disclosed |
| CN-102861610-B | Hyperbranched amido pyridine contained catalyst, preparation methods of catalyst and application of catalyst | NINGBO CHANGYANG TECHNOLOGY CO | 2014-05-07 | — | — | CN | disclosed |
| CN-102861610-A | Hyperbranched amido pyridine contained catalyst, preparation methods of catalyst and application of catalyst | NINGBO CHANGYANG TECHNOLOGY CO | 2013-01-09 | — | — | CN | disclosed |
| EP-1953147-A1 | HETEROCYCLIC COMPOUND AND MEDICINAL APPLICATION THEREOF | Japan Tobacco, Inc. (JP) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | EIF2AK2, GTF3C5, GTF3C1 | RECQL 4387/4885SMARCA2 4293/4885SMARCA4 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.